SAN JOSE, Calif.--(BUSINESS WIRE)--Reviva Pharmaceuticals is excited to announce that it has been selected as a Winner for the prestigious 2014 TiE50 Awards at the organization’s annual entrepreneurial conference, TiEcon in Santa Clara, California on May 16, 2014. Returning for the sixth year in a row, this year’s TiE50 was open to all technology companies worldwide.
“It is an honor and privilege to receive the TiE50 Award for 2014. We at Reviva Pharmaceuticals are proud that our commitment for developing new therapies to the treatment of patients with major unmet medical needs has been recognized through this award” – Laxminarayan Bhat, PhD, Founder and CEO, Reviva Pharmaceuticals, Inc.
“In the six short years since inception, the TiE 50 program has become a global brand that attracts thousands of companies worldwide for this recognition,” said Venktesh Shukla, president of TiE, Silicon Valley. “It is unique in terms of rigor of selection and the broad scope of companies that it reviews for this award and is one of TiE Silicon Valley’s most successful programs. It is also worth mentioning that this is the only awards recognition in technology to be held by a large global non-profit organization."
To determine the winner, a panel of experts will screen the companies and create a list of the “2014 TiE50 Top Startups.” This list will then be reviewed further by a screening committee of deep domain experts. About 100 of the best of the breed companies are selected to the elite TiE50 Finalist pool. Finally, this pool of TiE50 Finalists are judged by a panel of highly accomplished team made up of serial entrepreneurs, venture capitalists, angel investors, CEOs and well-rounded technology experts, to determine finalists and winners. Companies will be evaluated on three parameters: Business Model, IP Value and Leadership team.
At TiEcon 2014, 20 of the top startups from each of the five segments will be chosen to pitch their ideas, and winners will be announced on stage that evening.
This year at the event, attendees and TiE50 participants will also have the chance to hear from three previous TiE50 winners who have made successful exits recently: FireEye, Pearl Therapeutics and Rubicon Project.
“This year the TiE50 Awards Program screened more than 2800 companies from 27 countries. The finalist pool is represented by early through late stage companies. A star attraction of the conference is TiE50 Finalist presentations. Audiences are treated to great ideas and amazing technologies” said Ram K. Reddy, the program chair.
The TiE50 track record since its inception in May 2009 shows that 94% of the winners and finalists have been funded, attracting Billions in investments. Many of these companies have been acquired, merged or gone public. For further details on the TiE50, visit www.tie50.org.
About Reviva Pharmaceuticals, Inc.
Reviva is a privately-held, angel financed, fast growing, late-stage clinical development company located in San Jose, California. The company is focused on the discovery, development and commercialization of new, safe and highly effective novel, next generation therapeutic drugs using an integrated chemical genomics approach and proprietary chemistries. Reviva is developing Best-in-Class new drugs for central nervous system (CNS), metabolic, cardiovascular (CV), inflammation and pain indications. Its lead product RP5063, a broad spectrum antipsychotic drug is currently in Phase 3 development for schizophrenia.
Reviva’s leadership team has a strong background and a track record in successful and rapid product development, regulatory approval and commercialization. Founded in 2006, Reviva has been financed by angel investors comprised of medical doctors, successful entrepreneurs, and professionals in the healthcare and high-tech industries.
For additional information, please visit our website at www.revivapharma.com.